Functional and clinical results
| Control group (n=66) | Screened group (n=20) | p Value | |||
| Baseline | Follow-up | Baseline | Follow-up | ||
| FEV1 (% predicted) | 84.3 (6.3)* | 84.5 (18.0)* | 84.9 (21.0)† | 91.0 (15.6)† | *: NS; †: 0.03 |
| PC20 (mg/ml) | 1.50* | 1.67† | 3.35* | 4.81† | *: 0.05; †: 0.027 |
| Normal bronchial responsiveness (PC20 >8 mg/ml) | 14%* | 24.5%† | 42%* | 47.5%† | *: 0.02; †: NS |
| Clinical remission | 10%* | 16%† | 4.8%* | 34%† | *: NS; †: 0.02 |
Mean±SD (in parenthesis).
Clinical remission defined by a PC20 >8 mg/ml and no anti-asthma treatment.
* and † indicate the component used for comparison. NS, not statistically significant.